MERCK & CO., INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 126.2 USD | +0.36% |
|
-0.29% | +15.75% |
| Apr. 15 | Zacks Adjusts Price Target on Merck & Company to $132 From $128 | MT |
| Apr. 11 | Merck & Co Receives a Shareholder Proposal from The Bahnsen Family Trust | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
Merck & Co., Inc. specializes in the development, production, and marketing of therapeutic products and vaccines sold under prescription. Net sales break down by activity as follows:
- sale of pharmaceutical products (69.7%): for treating hypertension, osteoporosis, atherosclerosis, respiratory, bacterial and fungal, ophthalmologic, and urological diseases, acute migraine, hair loss in men, etc.;
- sale of vaccines (18%);
- sale of animal health products (9.4%);
- other (2.9%).
Net sales are distributed geographically as follows: the United States (45.9%), Europe/Middle East/Africa (24.5%), China (8.8%), Japan (6.1%), Asia/Pacific (6.1%), Latin America (4.3%) and other (4.3%).
Sector
Pharmaceuticals
Calendar
2024-04-25
- Q1 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
BUY
Number of Analysts
26
Last Close Price
126.2
USD
Average target price
137.2
USD
Spread / Average Target
+8.70%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +15.75% | 320B | |
| +28.79% | 676B | |
| +25.94% | 559B | |
| -5.84% | 356B | |
| +4.32% | 286B | |
| +4.00% | 213B | |
| +1.92% | 207B | |
| -7.93% | 199B | |
| -10.00% | 147B | |
| -7.82% | 142B |
- Stock Market
- Equities
- MRK Stock
- News Merck & Co., Inc.
- Berenberg Bank Adjusts Merck & Company Price Target to $125 From $115, Maintains Buy Rating
